公开(公告)号：US10316063B1

公开(公告)日：2019-06-11

申请号：US16283540

申请日：2019-02-22

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Steffen Walter ,  Jens Fritsche ,  Colette Song ,  Harpreet Singh

IPC: A61K38/08 ,  C07K7/08 ,  A61K39/00 ,  C07K7/06 ,  A61K38/17 ,  C12N9/64 ,  C12N5/0783

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US20190076477A1

公开(公告)日：2019-03-14

申请号：US16196440

申请日：2018-11-20

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  C07K7/08 ,  C12N5/0783 ,  C07K14/47 ,  C07K7/06 ,  A61K38/00

CPC classification number: A61K35/17 ,  A61K38/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C12N5/0638

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US20190076476A1

公开(公告)日：2019-03-14

申请号：US16196402

申请日：2018-11-20

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  C07K7/08 ,  C07K14/47 ,  C12N5/0783 ,  C07K7/06 ,  A61K38/00

CPC classification number: A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/495 ,  C07K14/7051 ,  C07K16/40 ,  C07K19/00 ,  C07K2317/34 ,  C07K2319/00 ,  C12N5/0638 ,  C12N9/0036 ,  C12N9/13 ,  C12N2502/1157 ,  C12Y208/02011

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10227381B2

公开(公告)日：2019-03-12

申请号：US14562156

申请日：2014-12-05

Applicant: immatics biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K38/00 ,  C07K7/06 ,  A61K39/00 ,  C07K7/08 ,  A61K35/17 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10100085B2

公开(公告)日：2018-10-16

申请号：US15226038

申请日：2016-08-02

Applicant: immatics biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  A61K35/17 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783 ,  A61K38/00

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US09950048B2

公开(公告)日：2018-04-24

申请号：US14934612

申请日：2015-11-06

Applicant: immatics biotechnologies GmbH

Inventor： Harpreet Singh ,  Steffen Walter ,  Toni Weinschenk ,  Norbert Hilf ,  Oliver Schoor ,  Claudia Trautwein

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/495 ,  C12N9/02 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K19/00 ,  C07K14/725 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/10

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/495 ,  C07K14/7051 ,  C07K16/40 ,  C07K19/00 ,  C07K2317/34 ,  C07K2319/00 ,  C12N5/0638 ,  C12N9/0036 ,  C12N9/13 ,  C12N2502/1157 ,  C12Y208/02011

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.